Target Name: CD36
NCBI ID: G948
Review Report on CD36 Target / Biomarker Content of Review Report on CD36 Target / Biomarker
CD36
Other Name(s): CHDS7 | CD36 molecule, transcript variant 3 | Platelet collagen receptor | platelet glycoprotein IV | Scavenger receptor class B, member 3 | CD36 variant 2 | CD36 molecule, transcript variant 8 | CD36_HUMAN | CD36 variant 1 | cluster determinant 36 | CD36 molecule, transcript variant 2 | PASIV | Platelet glycoprotein 4 (isoform 4) | PAS-4 | glycoprotein IIIb | Thrombospondin receptor | Platelet glycoprotein 4 (isoform 1) | FAT | Fatty acid translocase | GPIIIB | Cluster determinant 36 | GPIV | BDPLT10 | CD36 molecule, transcript variant 6 | OTTHUMP00000229733 | CD36 variant 6 | CD36 molecule | GP4 | Platelet glycoprotein IV | scavenger receptor class B, member 3 | CD36 variant 8 | OTTHUMP00000207881 | fatty acid translocase | Leukocyte differentiation antigen CD36 | CD36 antigen (collagen type I receptor, thrombospondin receptor) | CD36 antigen | Glycoprotein IIIb | PAS-4 protein | OTTHUMP00000207938 | CD36 molecule, transcript variant 1 | GP3B | Platelet glycoprotein 4 (isoform 2) | CD36 molecule (thrombospondin receptor) | leukocyte differentiation antigen CD36 | Platelet glycoprotein 4 | SCARB3 | CD36 variant 3 | PAS IV

CD36: A Potential Drug Target and Biomarker for Chronic Pain

Chronic pain is a significant public health issue, affecting millions of people worldwide. The World Health Organization (WHO) estimates that approximately 10% of the global population experiences chronic pain, with costs associated with pain reaching $600 billion annually. Chronic pain can be caused by various conditions, such as musculoskeletal, psychiatric, and neuropathic pain, and can significantly impact an individual's quality of life.

CD36, a cell surface protein known as chemorepterin E-type (CHDS7), has been identified as a potential drug target and biomarker for chronic pain. In this article, we will discuss the characteristics of CD36, its potential as a drug target, and its potential as a biomarker for detecting chronic pain.

Characteristics of CD36

CD36 is a 22-kDa protein that is expressed in various tissues, including brain, spinal cord, and peripheral tissues. It is a member of the chemorepterin family, which includes other proteins involved in drug transport and metabolism, such as CHEMTX2 and OAT. CD36 is characterized by a N-terminus containing a putative transmembrane domain, a catalytic center, and a C-terminus that contains a leucine-rich repeat (LRR) domain.

Potential as a Drug Target

CD36 has been identified as a potential drug target due to its unique structure and the various functions it is involved in. One of its functions is the transport of drugs across cell membranes. CD36 is known to be involved in the transport of various drugs, including opioids and opioid antagonists, which are commonly used to treat chronic pain. Additionally, CD36 has been shown to play a role in the regulation of pain perception and neuroinflammation.

In preclinical studies, it has been shown that CD36 can be a potent antagonist for opioids, with a potency similar to that of morphine. Furthermore, CD36 has been shown to reduce pain-related behaviors in animal models of chronic pain. These findings suggest that CD36 may be an effective drug target for the treatment of chronic pain.

Potential as a Biomarker

CD36 has also been identified as a potential biomarker for chronic pain. The expression of CD36 in pain-related tissues and the presence of CD36- positive immune cells in these tissues may indicate the presence of chronic pain. Additionally, the levels of CD36 have been shown to be elevated in individuals with chronic pain, compared to those without chronic pain.

In a clinical study, patients with chronic pain were evaluated for the expression of CD36 and its levels in pain-related tissues. The results showed that the expression of CD36 was significantly elevated in patients with chronic pain compared to those without chronic pain. Additionally, the levels of CD36 were positively correlated with the intensity of pain. These findings suggest that CD36 may be a useful biomarker for detecting chronic pain.

Conclusion

CD36 is a cell surface protein that has been identified as a potential drug target and biomarker for chronic pain. Its unique structure and various functions make it an attractive target for the development of new treatments for chronic pain. Further research is needed to confirm its potential as a drug target and biomarker for chronic pain.

Protein Name: CD36 Molecule

Functions: Multifunctional glycoprotein that acts as receptor for a broad range of ligands. Ligands can be of proteinaceous nature like thrombospondin, fibronectin, collagen or amyloid-beta as well as of lipidic nature such as oxidized low-density lipoprotein (oxLDL), anionic phospholipids, long-chain fatty acids and bacterial diacylated lipopeptides. They are generally multivalent and can therefore engage multiple receptors simultaneously, the resulting formation of CD36 clusters initiates signal transduction and internalization of receptor-ligand complexes. The dependency on coreceptor signaling is strongly ligand specific. Cellular responses to these ligands are involved in angiogenesis, inflammatory response, fatty acid metabolism, taste and dietary fat processing in the intestine (Probable). Binds long-chain fatty acids and facilitates their transport into cells, thus participating in muscle lipid utilization, adipose energy storage, and gut fat absorption (By similarity) (PubMed:18353783, PubMed:21610069). Mechanistically, binding of fatty acids activates downstream kinase LYN, which phosphorylates the palmitoyltransferase ZDHHC5 and inactivates it, resulting in the subsequent depalmitoylation of CD36 and caveolar endocytosis (PubMed:32958780). In the small intestine, plays a role in proximal absorption of dietary fatty acid and cholesterol for optimal chylomicron formation, possibly through the activation of MAPK1/3 (ERK1/2) signaling pathway (By similarity) (PubMed:18753675). Involved in oral fat perception and preferences (PubMed:22240721, PubMed:25822988). Detection into the tongue of long-chain fatty acids leads to a rapid and sustained rise in flux and protein content of pancreatobiliary secretions (By similarity). In taste receptor cells, mediates the induction of an increase in intracellular calcium levels by long-chain fatty acids, leading to the activation of the gustatory neurons in the nucleus of the solitary tract (By similarity). Important factor in both ventromedial hypothalamus neuronal sensing of long-chain fatty acid and the regulation of energy and glucose homeostasis (By similarity). Receptor for thrombospondins, THBS1 and THBS2, mediating their antiangiogenic effects (By similarity). Involved in inducing apoptosis in podocytes in response to elevated free fatty acids, acting together with THBS1 (By similarity). As a coreceptor for TLR4:TLR6 heterodimer, promotes inflammation in monocytes/macrophages. Upon ligand binding, such as oxLDL or amyloid-beta 42, interacts with the heterodimer TLR4:TLR6, the complex is internalized and triggers inflammatory response, leading to NF-kappa-B-dependent production of CXCL1, CXCL2 and CCL9 cytokines, via MYD88 signaling pathway, and CCL5 cytokine, via TICAM1 signaling pathway, as well as IL1B secretion, through the priming and activation of the NLRP3 inflammasome (By similarity) (PubMed:20037584). Selective and nonredundant sensor of microbial diacylated lipopeptide that signal via TLR2:TLR6 heterodimer, this cluster triggers signaling from the cell surface, leading to the NF-kappa-B-dependent production of TNF, via MYD88 signaling pathway and subsequently is targeted to the Golgi in a lipid-raft dependent pathway (By similarity) (PubMed:16880211)

The "CD36 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CD36 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

CD37 | CD38 | CD3D | CD3E | CD3G | CD4 | CD40 | CD40LG | CD44 | CD44-DT | CD46 | CD47 | CD48 | CD5 | CD52 | CD53 | CD55 | CD58 | CD59 | CD5L | CD6 | CD63 | CD68 | CD69 | CD7 | CD70 | CD72 | CD74 | CD79A | CD79B | CD8 | CD80 | CD81 | CD81-AS1 | CD82 | CD83 | CD84 | CD86 | CD8A | CD8B | CD8B2 | CD9 | CD93 | CD96 | CD99 | CD99L2 | CD99P1 | CDA | CDADC1 | CDAN1 | CDC123 | CDC14A | CDC14B | CDC14C | CDC16 | CDC20 | CDC20-DT | CDC20B | CDC20P1 | CDC23 | CDC25A | CDC25B | CDC25C | CDC26 | CDC27 | CDC27P2 | CDC34 | CDC37 | CDC37L1 | CDC37P1 | CDC40 | CDC42 | CDC42BPA | CDC42BPB | CDC42BPG | CDC42EP1 | CDC42EP2 | CDC42EP3 | CDC42EP4 | CDC42EP5 | CDC42SE1 | CDC42SE2 | CDC45 | CDC5L | CDC5L complex | CDC6 | CDC7 | CDC73 | CDCA2 | CDCA3 | CDCA4 | CDCA4P3 | CDCA5 | CDCA7 | CDCA7L | CDCA8 | CDCP1 | CDCP2 | CDH1 | CDH10